Last updated
Boehringer Ingelheim: M&A Activity
Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.
Source: GNW — Germany
- Who
- Boehringer Ingelheim · Biotech & Pharma · Switzerland
- What happened
- Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.
- When
- 2026-08-11
- Source
- GNW — Germany
- So what
- Consolidation shifts the leadership question from growth to integration.
The leadership read
Consolidation shifts the leadership question from growth to integration. For Boehringer Ingelheim in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across EMEA, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: This lands while the Talent Market Index reads 95.4 (Cool) — down 5.3 versus the prior month — and EMEA signal share is rising (+5pts).
Boehringer Ingelheim: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Americas signal flow; 8 tracked across 152 days.
MitchelLake in this thematic
Also at Boehringer Ingelheim →
More signals across Biotech & Pharma
M&A Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
M&A Activity · EMEA
Gilead Sciences →Gilead Sciences acquired Tubulis, a Germany-based clinical-stage biotechnology company for up to USD 5.0 billion
Leadership Change · EMEA
BioNTech →BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).
Capital Raising · EMEA
Neobe Therapeutics →UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.
Leadership Change · EMEA
Harbour BioMed →Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.
Capital Raising · EMEA
mbiomics →mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
